It depends entirely on what you measure, and claims of a single multiplier (4-fold, 10-fold, or 300-fold) are each quoting one endpoint while ignoring the rest.

On the clinically usable dose-equivalence scale, a typical low-dose pill is roughly 4 to 7 times a standard menopausal estrogen dose, which is the defensible version of this claim. But dose is not the main reason the pill and standard hormone therapy differ in safety. The synthetic estrogen in most pills is processed by the liver very differently than the estrogen used in standard hormone therapy, and that liver effect, not the raw dose, is what mainly drives the higher clotting risk associated with pills in older women.

What to know about this answer

Several respected clinicians have repeated a strength-multiplier for the pill on camera, and the multipliers they use range from 3-to-4-fold to 300-fold. The source material treats this as a case where careful pharmacology contradicts popular framing, even among credentialed experts.

What the research shows, and which source each finding rests on

The estrogen in most combined pills (ethinyl estradiol) and the estrogen in standard hormone therapy (17-beta estradiol, structurally identical to the body's own hormone) are different molecules with different metabolism, not simply different doses of the same substance.

E[1]

At the estrogen receptor itself, ethinyl estradiol and estradiol act within roughly the same order of magnitude of potency; a commonly repeated claim of a 300-fold receptor advantage for the pill's estrogen is not supported by receptor-binding data.

D[2]

The potency difference instead comes mainly from the liver: in a controlled study, the pill's synthetic estrogen was 4- to 18-fold more potent than estradiol on liver-protein measures, but far less different on hormone-suppression measures, in the very same women.

D[3]

On the standard clinical dose-equivalence scale, 5 micrograms of the pill's estrogen is roughly equivalent to 1 milligram of oral estradiol or 50 micrograms of transdermal estradiol, meaning a 20-microgram pill is roughly 4 times, and a 30-35 microgram pill roughly 6 to 7 times, a standard menopausal estrogen dose.

E[4]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

the pill is many times stronger, full stop

some clinicians in the field, using varying multipliers

Clinicians make this argument to explain why the pill can control bleeding when standard menopausal doses cannot, and to reassure patients that standard hormone therapy doses are comparatively small.

E[5]

the multiplier depends entirely on what is measured, and the real story is the liver effect, not the dose

the pharmacology literature and a more precise reading of the same clinicians' own data

A single head-to-head study measured the same estrogens on multiple outcomes in the same women and found the ratio ranged from roughly 1-to-2-fold up to 18-fold depending on which body system was measured; the number that matters for safety is not a strength multiplier but whether the estrogen is taken orally (with a first-pass liver effect) or transdermally (without one).

D[3]

What would settle it: This is a matter of correcting which endpoint is being cited rather than a data gap; the underlying pharmacology studies already exist and simply need to be read for the specific measurement being described.

What is really going on here

  1. Any single multiplier for pill strength versus hormone therapy strength is quoting one endpoint (often a liver-protein measure) and hiding the others; ask what was actually measured.
  2. The reason a switch to standard hormone therapy is generally recommended around age 50 is mainly about route (oral versus through-the-skin) and molecule, not simply about lowering a dose.
  3. The reverse argument, that hormone therapy must be safe because it is only a fraction of the pill's dose, is also a dose argument standing in for a route-and-molecule argument, and it does not hold if the hormone therapy itself is taken orally rather than transdermally.

Questions for your doctor

  1. If I switch from the pill to hormone therapy, will it be taken orally or through the skin, and does that matter for me?
  2. What specifically changes in my risk profile with this switch, beyond the estrogen dose?
  3. Is my current pill dose set for contraception, for symptom control, or both?
  4. How would we know if the dose or the delivery method needs adjusting?

Questions with no answer yet

Is there a single strength number that fairly compares the pill to hormone therapy, or does the honest answer depend entirely on which body system is being measured?

Studied and negative

What is known: A single head-to-head study measured the same estrogens on multiple outcomes in the same women and found the ratio ranged from roughly 1-to-2-fold up to 18-fold depending on which body system was measured; several respected clinicians have nonetheless repeated a single multiplier, from 3-to-4-fold up to 300-fold, on camera.

What would test it: This is already answered by the existing pharmacodynamic study; what would help is consistently specifying which endpoint any quoted multiplier refers to.

Since the liver effect, not the raw dose, appears to drive the pill's higher clotting risk, would a much lower-dose ethinyl estradiol pill still carry a disproportionate liver effect?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Ethinyl estradiol has never been studied at menopausal-equivalent low doses for menopausal indications; the assumption that a very low dose would still carry a disproportionate liver effect is reasoned from existing higher-dose data, not directly tested.

What would test it: A dedicated study of ethinyl estradiol at menopausal-equivalent low doses, measuring the same liver and clotting-related parameters used in the original comparative studies.

Sources

  1. 1.Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment.Stanczyk FZ, Archer DF, Bhavnani BR. Ethinyl estradiol and 17beta-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception 2013;87(6):706-27. · Review, opinion or mechanism
  2. 2.Estrogenic effects of natural and synthetic compounds including tibolone assessed in Saccharomyces cerevisiae expressing the human estrogen alpha and beta receptors.Hasenbrink G, Sievernich A, Wildt L, Ludwig J, Lichtenberg-Frate H. Estrogenic effects of natural and synthetic compounds including tibolone assessed in Saccharomyces cerevisiae expressing the human estrogen alpha and beta receptors. FASEB J 2006;20(9):1552-4. · Comparative or small study
  3. 3.Comparison of pharmacodynamic properties of various estrogen formulations.Mashchak CA, Lobo RA, Dozono-Takano R, Eggena P, Nakamura RM, Brenner PF, Mishell DR. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982;144(5):511-8. · Comparative or small study
  4. 4.Postmenopausal Hormone Therapy-Local and Systemic: A Pharmacologic Perspective.Smith T, Sahni S, Thacker HL. Postmenopausal hormone therapy - local and systemic: a pharmacologic perspective. J Clin Pharmacol 2020;60(S2):S74-S85. · Review, opinion or mechanism
  5. 5.Vonda Wright, MD (video transcript).Review, opinion or mechanism

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides